At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 146 enrolled
Drug / intervention
SAGE-324 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Response Study of SAGE-324 for the Treatment of Essential Tremor
In Brief
A Phase 2 clinical trial evaluating SAGE-324 and SAGE-324 Matched Placebo for Essential Tremor. Completed, enrolled 146 participants across 51 sites.
Detailed Summary
The primary purpose of this study is to evaluate the dose-response relationship of different doses of SAGE-324 on upper extremity tremor in participants with essential tremor (ET) in the monotherapy cohort.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEssential Tremor
CountriesUnited States
CollaboratorsBiogen
Timeline
Phase 2CompletedFinished
20222023202420252026
First PostedDec 2021
Enrollment StartJan 2022
Primary CompletionMay 2024
Study CompletionMay 2024
TodayJul 2026
First PostedDec 29, 2021
Enrollment StartJan 5, 2022
Primary CompletionMay 2, 2024
Study CompletionMay 16, 2024
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 4.5 years ago
Interventions
SAGE-324drug
SAGE-324 oral tablets.
SAGE-324 Matched Placebodrug
SAGE-324 matched placebo oral tablets.